Biogen (BIIB) announced that the board of directors has elected Maria Freire as chair of the board of directors, effective immediately following the company’s 2026 annual meeting of stockholders, scheduled to take place on June 9. Freire will succeed Caroline Dorsa who has decided to retire from the Biogen board of directors and not to stand for reelection at the annual meeting. Freire joined the Biogen board in 2021.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target raised to $187 from $178 at Wedbush
- Biogen: Leqembi Partnership and Subcutaneous Expansion Drive Multi‑Year Alzheimer’s Growth Opportunity
- Biogen price target raised to $233 from $217 at RBC Capital
- Biogen price target raised to $215 from $175 at TD Cowen
- Biogen price target raised to $196 from $165 at BMO Capital